NeurologyMigrainereflectance confocal microscopy
Atogepant Shows Better Tolerability and Efficacy Than Topiramate in Migraine Prevention: TEMPLE Trial Results
By MedXY|Jul 25, 2026
The phase 3b TEMPLE trial found that atogepant 60 mg once daily led to fewer discontinuations due to adverse events and better migraine reduction than topiramate over 24 weeks.
